Novel marker may help diagnose aggressive cancers with poor prognosis

A study published in The Journal of Pathology reveals that many cancers that carry a poor prognosis express an altered form of human telomerase reverse transcriptase (hTERT), an enzyme that regulates the expression of multiple genes.

Scientists previously linked a modification called phosphorylation at a particular location on the hTERT enzyme to poor prognosis in liver and pancreatic cancers. Now the team has built on this research to show that elevated levels of this phosphorylated hTERT are common in other types of cancer as well, especially when the cancers have aggressive features.

“We developed a monoclonal antibody and an automated immunostaining system to detect phosphorylated hTERT in tissue samples, thus providing a basis for the development of a novel clinical diagnostic tool to identify patients with aggressive cancer,” said lead author Yoko Matsuda, MD, PhD, of Kagawa University, in Japan.

URL Upon Publication: https://onlinelibrary.wiley.com/doi/10.1002/path.5876

Additional Information

NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact:

Dawn Peters +1 781-388-8408 (US)
newsroom@wiley.com
Follow us on Twitter @WileyNews

About the Journal

The Journal of Pathology serves as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on tissue based studies. The journal publishes high-impact research that furthers our understanding the pathophysiological and pathogenetic mechanisms of human disease.

About Wiley

Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at  Wiley.com, like us on Facebook and follow us on Twitter and LinkedIn.